Information Provided By:
Fly News Breaks for January 25, 2017
TXMD
Jan 25, 2017 | 07:30 EDT
After touring a compounding pharmacy, Jefferies analyst Matthew Andrews says the market opportunity for TherapeuticsMD's TX-001 is underappreciated. He disagrees with the bear thesis of a $50M market opportunity, feeling the treatment of vasomotor symptoms related to menopause has a market of $714M-$893M. The analyst calls TherapeuticsMD a top small-cap pick for 2017 and keeps a Buy rating on the shares with an $18 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.